Genflow Biosciences Share Discussion Threads

[moneymunch] 17/1/2024 18:33

Nice on Northeast, a great find and thanks for posting. Excitement building. Gl :-)


The Company is headquartered in London and has a Belgian R&D subsidiary, Genflow Biosciences SRL (“Genflow BE”) that was established in 2020. Genflow BE’s location enables it to benefit from the relatively low operating costs and from substantial (non diluting) grants that support its research and development that are available from Belgium’s Wallonia region.

In addition to pre-clinical activities, Genflow seeks an earlier path to revenue with respect to Werner Syndrome, a rare progressive disorder characterised by the appearance of unusually accelerated ageing.

Genflow intends to conduct a European Phase I/II clinical trial with Werner Syndrome patients. The Company believes that positive clinical data will be the source of significant value creation through, potential acquisition or licensing arrangements. Moreover, a trial in Werner Syndrome will support the path to a specific aging indication.

[northeast14] 17/1/2024 18:03

As part of the Wallonia Recovery Plan, the Walloon Government is launching an innovation partnership dedicated to ATMPs (innovative therapy drugs) with a budget of €81 million - 60% public money and 40% private business funds - over 3 years, in collaboration with the BioWin cluster - The Health Cluster of Wallonia and the Public Service of Wallonia.

🔬 The partnership involves 26 partners and aims to maintain leadership and strengthen the sector in Wallonia by establishing new collaborations between academic partners, a research centre and companies of all sizes.

💊 Advanced therapy drugs are new generation biomedicines aimed at meeting unmet medical needs (breast and colorectal cancer, solid tumours, liver fibrosis, central nervous system pathologies...). They represent one of the most innovative and promising revolutions in modern medicine.

👩🏻🔬👨7996;🔬It is estimated that more than 470 direct and 1,200 indirect jobs will be created in the next five years. The ATMP sector in Wallonia already represents 6,000 direct and indirect jobs.

The ATMP PIT is a unique opportunity for the development and growth of a sector of importance for the future of Wallonia. Genflow are on the bottom of there LinkedIn post! Game on!!!

[luckyabbeygale] 15/1/2024 11:47

I was watching anti aging videos on youtube last night.
I noticed that billionaires are now having blood tranfusions from teenagers, and their blood is making them look decades younger.

In another video they was on about an anti aging pill that will be out in ten years time, that will be available to everyone. The pill will cost around 10K a year to each person who is interested in living for thousands of years.

I think Genflow will be ahead of the game and will create its own anti aging pill before this one comes out in ten years time.

[moneymunch] 12/1/2024 19:52

Perfectly poised and hopefully wide awake, very soon!!! Gl :-)

[moneymunch] 11/1/2024 19:18

Interestingly enough, Estee Lauder's new longevity product is the patented Sirtivity-LP technology, and appear to be investing heavily into the longevity space. Gla ;-)


Estée Lauder targets age reversal with Stanford Center on Longevity partnership
By Julia Wray |

Published: 15-Dec-2023
Ingredients Skin Care

The brand will also launch a Longevity Collective in January to coincide with a new skin care product promising ‘visible age reversal’

Longevity is fast becoming a beauty industry buzzword as the health and wellness sector evolves to address our longer lifespans.

Now Estée Lauder has reaffirmed its investment into ‘curing’ ageing by partnering with the Stanford Center on Longevity.

Estée Lauder Companies’ flagship brand announced an initial three-year commitment to the centre’s new Program on Aesthetics & Culture.

This, it said, would help fund a wide range of research activities, including ‘New Map of Life’ post-doctoral fellowships and other work to advance the understanding of perceptions on longevity and vitality.

“Extended life expectancy offers us the opportunity to gain a deeper understanding about how people subjectively experience vitality and communicate this experience to others,” said Laura Carstensen, Director of the Stanford Center on Longevity, of Estée Lauder’s support.

“We believe that skin, as the largest organ, plays a sizeable role in conveying this vitality.”

Estée Lauder will also mark the new year by establishing its Longevity Collective, a curated group of influential experts and global pioneers in longevity science and lifestyle.

From January 2024, the Estée Lauder Longevity Collective will serve as a brand advisory board, bringing new insights, research findings and resources to inform the brand’s ongoing approach to skin longevity research.

Collective members include Dr Nadine Pernodet, the brand’s Senior Vice President, Bioscience, Global R&D; long-term Estée Lauder partner Dr Danica Chen, Professor of Metabolic Biology, Nutritional Sciences & Toxicology at the University of California Berkeley; and Serena Liang Jing, a ‘New Map of Life’ Fellow at the Stanford Center on Longevity.

Experts from the Buck Institute for Research on Aging, the Center of Aging Research & Clinical Care at Weill Cornell Medicine, and the Stanford University School of Medicine will also be involved.

Next month will further see Estée Lauder launch Re-Nutriv Ultimate Diamond Transformative Brilliance Soft Crème.

The new sku is made with the brand’s patented Sirtivity-LP technology, which reveals visible age reversal starting at 14 days of use.

It is said to be the result of two decades of Estée Lauder’s study into the role of sirtuins – commonly known as ‘longevity proteins’ – in skin.

“The Estée Lauder brand has always been at the forefront of skin science,” said Justin Boxford, Global Brand President, Estée Lauder.

“Longevity is one of the fastest growing movements in the beauty and wellness industries, with multi-generational consumer interest in biohacking and age-reversal practices at an all-time high.”

He added: “Estée Lauder has been pioneering skin longevity research for more than 15 years, and we already have the proven technology to reveal visible age reversal.

“We see this as a truly pivotal moment for the brand to disrupt the industry, changing what we know about skin ageing and reimagining skin care for the future.”

[moneymunch] 11/1/2024 19:09

The Future Is Bright

To a certain extent, the things you can do now to prevent premature aging is to live a healthy lifestyle that limits stress, follow a healthy diet, exercise regularly, and so on.

Fortunately, the future’s looking bright with medical biotechnological advancements.

Genflow Biosciences works with major anti-aging research centers across the globe and believes that the SIRT6 gene is a master regulator of managing healthy aging and the potential therapeutic target preserve function.

These discoveries are in pursuit of finding disruptive anti-aging drugs. In fact, clinical testing is starting to happen, albeit in the infancy stages, making way for potentially transformative medicines.

[moneymunch] 11/1/2024 19:06

GenFlow Biosciences

1,399 followers
1h

At GenFlow Biosciences (LSE: GENF)(OTCQB: GENFF), we're passionate about unveiling the mysteries of aging. Our latest article dives deep into premature aging, offering valuable insights on how your lifestyle choices and genetic factors play a crucial role. Learn about the impacts on various body systems and get expert tips for staying youthful and healthy.

Read it here:

#longevity #aging #healthspan

[moneymunch] 10/1/2024 14:17

GenFlow Biosciences

1,399 followers

21h

In Sardinia, GenFlow Biosciences (LSE: GENF)(OTCQB: GENFF) is initiating a pioneering human proof-of-concept Phase I/II trial for Werner Syndrome, which serves as a model for studying premature aging in humans. Investigating its causes offers valuable insights into the aging process and may lead to strategies that enhance overall health and longevity.

Learn more about Werner here:

#Werner #longevity #aging #healthspan

[kubera369] 08/1/2024 15:13

Nice buys All the small time profit takers taken out in a swoop

[moneymunch] 07/1/2024 22:19

Excitement building Northeast, and plenty of UPside coming this way in anticipation of news, which could be game changing with any luck. Gl :-)

[northeast14] 07/1/2024 19:45

Looking forward to a positive week ahead

[moneymunch] 07/1/2024 11:15

Genflow Corporate Power Point Presentation

[moneymunch] 06/1/2024 06:46

Yes indeed kubera, in the meantime the FDA are moving closer to award full approval ( trial result dependent ) for a longeity drug for dogs, so highly significant for Genflow's GF-4001 Non-Human Pipeline Anti-aging for veterinary use (dogs) and so every chance we could get confirmation of the planned Pivotal trial anti-aging for dogs and an annoucement of a JV Veterinary partner. Gl ;-)

29/11/23

A San Francisco-based biotechnology firm is on a mission to keep your best friend around a little longer.

Loyal is spearheading the development of an experimental drug geared toward extending the lifespan of large-breed dogs by a minimum of one year. On Tuesday, it secured conditional approval for its medication from the U.S. Food and Drug Administration.

The landmark approval clears the way for more extensive clinical trials. It also marks the first time the agency has endorsed a longevity drug.

[kubera369] 05/1/2024 22:34

Many millions can arrive a lot sooner Moneymunch.As soon as the FDA confirms Ageing as a disease then expect fireworks here

[moneymunch] 05/1/2024 18:44

Lol....very funny and utter nonsense, this is all about Genflow developing a safe, ethical delivery system of a variant of the Sirt6 gene found in centenarians, which is hoped to improve healthspan and extend lifespan by a couple of decades or more to begin with...Sirt6 is thought to be the most potent and fundamental gene involved in multiple disease targets and Genflow's R&D confirm compelling data as they progress towards human clinical trials in NASH in 2025 and update progress on the status of their planned clinical trials in Werner Disease and also dogs ...successful clinical trial results on any of their targets would increase Genflow's m/c by many millions of dollars, and catapult Genflow into mid cap range Bio thereafter, as Eric promotes Sirt6's healthspan and longevity credentials to a long list of Major pharma's who would be prepared to pay many of millions of dollars to own little old Genflow...Can't wait!!! Gl :-)

[luckyabbeygale] 05/1/2024 16:54

By being a share holder in this. You then gain the right to be one of the first people on earth to have the special longevity treatment. I have heard they can make people live up to 1,000 years longer.

Another thing is if you are not a shareholder then you most likely will not be able to afford this. Investing £2,000 or more will enable you to afford this longevity treatment. As by then this share will be worth at least 100 times more.

The cost is estimated at something like £200,000 per person for when it first comes out.

[moneymunch] 05/1/2024 15:30

Pesky profit takers Lawson, which has pegged the share price back a tad, as seen in all the Biotech risers today, but still great timing to buy before expected news is released, which hopefully will see the share price sail past 2p, 3p and more and plenty to look forward to this year...Gla holders:-)

[kubera369] 05/1/2024 14:42

Totally agree to every word you have mentioned here Eric has always delivered and is a experienced businessman Look at the team at Genflow and the patents they have already in the bag.They are the only bio science company in Europe and the UK with first mover advantage and are working on multiple solutions regarding Sirt6 No other company has gone that far - not even Altos Labs where we heavy hitter investors like Jeff BezosThis is simply priced too low in regards to Mcap / share price compared to peers in the sector and Genflow are simply too far ahead of the game already Loads of news incoming in the hottest sector of this year and beyond - Longevity and Anti Ageing as more of the world is waking up by taking their own health in their hands via holistic solutions The people have lost faith and trust of big pharma and modern day G.Ps post Covid.Wake up and smell the coffee.Simply buy in and sit down and watch this little acorn sprout into a huge mountainess treeGood luck not that you need it here

[aberdeano] 05/1/2024 14:24

Well we know it’s gonna be good news. We know what’s happening with the grants and how the pipeline is looking for this year then on into human trials hopefully early 25. The next update will be super positive. I can’t really think of what “bad” could come at this stage? Not getting grants/funding? Nah it’s in the bag! Anyone who jumped in today won’t regret it.

[babbler] 05/1/2024 13:59

The news is due. It will come. Overdue now. Could be good could be bad. Good it's back to 2 plus. Bad... Game over. Place your bets.

[lawson27] 05/1/2024 13:08

moneymunch......"Great timing Lawson"
Now looking a tad premature, FOMO :-(

[moneymunch] 05/1/2024 11:28

Looks like UK Biotech is hot hot hot this year and Genflow's tiny market cap looks extremely attractive commensurate to near term news and exciting prospects and potential going forward, in run up to human trials 2025!!! Gla :-)

[moneymunch] 05/1/2024 10:12

Rene up on invivo results etc, and looking good along with very positive sentiment on UK Biotech....Genflow are expecting imminent news on 4 x invivo Final Results. Gl :-)


Genflow

28/9/23

The Company continues to maintain a secure financial position and has sufficient cash reserves until March 2025. This is inclusive of grant funding which has been approved at the time of reporting and is due to be received in the coming months. The Company continues to seek further non-dilutive research grants which management will use to expedite specific phases of planned research and development.

......

The Company is conducting in-vivo evaluations of its centenarian SIRT6 gene therapy in four different NASH mice models in conjunction with four leading partners in the field: The University of Liverpool, UK, The University of Rochester, US, the International Clinical Research Center (FNUSA-ICRC) , Czech Republic and Physiogenex, France.

These studies have been wide reaching and have included the analysation of over 700 mice, with the intention of understanding the efficacy and safety of the Company's drug candidate in animal models with NASH and has generated essential information in preparation for clinical trials in humans. Final reports are expected by the end of 2023.

[tomavery19] 05/1/2024 09:43

Rene guys about to go vertical